Human papillomavirus, genital warts, and vaccines

Journal of Microbiology, Immunology and Infection

Volumn 42, Issue 2, 2009, Pages 101-106

  Hsueh, Po Ren ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Condylomata acuminata; Human papillomavirus; Papillomavirus vaccines

Indexed keywords

IMIQUIMOD; MITOPODOZIDE; PLACEBO; RECOMBINANT VACCINE; TRICHLOROACETIC ACID; WART VIRUS VACCINE;

AGE DISTRIBUTION; ANUS CANCER; CANCER PREVENTION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COLORECTAL CANCER; CONDOM; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG INDICATION; ELECTROSURGERY; ERADICATION THERAPY; HEALTH CARE COST; HETEROSEXUAL MALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 6; HUMAN PAPILLOMAVIRUS TYPE 73; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; LOW LEVEL LASER THERAPY; MALE HOMOSEXUAL; NONHUMAN; PENIS DISEASE; PRECANCER; PREVALENCE; PUBLIC HEALTH PROBLEM; REVIEW; RISK REDUCTION; SEX RATIO; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SPAIN; SURVIVAL; TAIWAN; UNITED STATES; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DYSPLASIA; VAGINA DISEASE; VIRUS INFECTION; VIRUS LIKE AGENT; VULVA DISEASE; WART VIRUS;

CONDYLOMATA ACUMINATA; FEMALE; HUMANS; INCIDENCE; MALE; PAPILLOMAVIRUS VACCINES;

EID: 67651093960     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Wiley D, Masongsong E. Human papillomavirus: the burden of infection. Obstet Gynecol Surv. 2006;61(Suppl 1):S3-14.
2. Saslow D, Castle PE, Cox JT, Davey DD, Einstein MH, Ferris DG, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007;57:7-28. (Pubitemid 46148088)
3. Wang SS, Hildesheim A. Viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr. 2003;31:35-40.
4. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997;102:3-8. (Pubitemid 127695953)
5. Insinga RP, Dasbach EJ, Myers ER. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis. 2003;36:1397-1403
6. Castellsagué X, Cohet C, Puig-Tintoré LM, Acebes LO, Salinas J, Martin MS, et al. Epidemiology and cost of treatment of genital warts in Spain. Eur J Public Health. 2009;19:106-110
7. Lattimore S, Yin Z, Logan L, Rice B, Thornton A, Molinar D, et al. Situation of HIV infections and STIs in the United Kingdom in 2007. Euro Surveill. 2008;13 pii:19059.
8. Fenton KA, Lowndes CM. Recent trends in the epidemiology of sexually transmitted infections in the European Union. Sex Trans Infect. 2004;80:255-263 (Pubitemid 39070785)
9. Langley PC, White DJ, Drake SM. The costs of treating external genital warts in England and Wales: a treatment pattern analysis. Int J STD AIDS. 2004;15:501-508 (Pubitemid 39120231)
10. Monsonégo J, Breugelmans JG, Bouée S, Lafuma A, Bénard S, Rémy V. Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France. Gynecol Obstet Fertil. 2007;35:107-113 [Article in French]. (Pubitemid 46304309)
11. Dasbach EJ, Insinga RP, Yang YC, Pwu RF, Lac C, Elbasha EH. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan. Asian Pac J Cancer Prev. 2008;9:459-466
12. Tsao YP, Yang KY, Han CP, Yin CS, Yang YF, Chen SL. Genital human papillomavirus infections in Taiwan. Int J Gynaecol Obstet. 1994;44:39-45. (Pubitemid 24016758)
13. Lee YM, Leu SY, Chiang H, Fung CP, Liu WT. Human papillomavirus type 18 in colorectal cancer. J Microbiol Immunol Infect. 2001;34:87-91. (Pubitemid 32641337)
14. Tay SK, Ngan HY, Chu TY, Cheung AN, Tay EH. Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan. Vaccine. 2008;26(Suppl 12):M60-70.
15. Chen CA, Liu CY, Chou HH, Chou CY, Ho CM, Twu NF, et al. The distribution and differential risks of human papillomavirus genotypes in cervical preinvasive lesions: a Taiwan Cooperative Oncologic Group Study. Int J Gynecol Cancer. 2006;16:1801-1808
16. Castle PE. Beyond human papillomavirus: the cervix, exogenous secondary factors, and the development of cervical precancer and cancer. J Low Genital Tract Dis. 2004;8:224-230
17. Von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol. 2001;11:598-603. (Pubitemid 33044469)
18. Scheinfeld N, Lehman DS. An evidence-based review of medical and surgical treatments of genital warts. Dermatol Online J. 2006;12:5.
19. Van der Meijden WI, Notowicz A, Blog FB, Langley PC. A retrospective analysis of costs and patterns of treatment for external genital warts in The Netherlands. Clin Ther. 2002;24:183-196 (Pubitemid 34117533)
20. Maw RD, Reitano M, Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS. 1998;9:571-578 (Pubitemid 28474812)
21. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis. 2000;181:1911-1919 (Pubitemid 30416152)
22. Barr E, Sings HL. Prophylactic HPV vaccines: new interventions for cancer control. Vaccine. 2008;26:6244-6257
23. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-1927 (Pubitemid 46740302)
24. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928-1943 (Pubitemid 46740303)
25. Carter JJ, Madeleine MM, Shera K, Schwartz SM, Cushing-Haugen KL, Wipf GC, et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res. 2001;61:1934-1940 (Pubitemid 32692010)
26. Keam SJ, Harper DM. Human papillomavirus types 16 and 18 vaccine (recombinant, AS04 adjuvanted, adsorbed) [Cervarix]. Drugs. 2008;68:359-372 (Pubitemid 351225812)
27. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol. 2008;110(Suppl 1):S18-25.
28. Schwarz TF. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention. Expert Rev Vaccines. 2008;7:1465-1473
29. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet. 2006;367:1247-1255